NCT02151448 · OUTCOME

Tumor Necrosis Factor (TFNα) Cytokine Levels

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies · Source last updated 2020-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: pg/mL
Interval / dispersion: Standard Deviation
Time frame: Prior to vaccine administration (Week 1), prior to vaccine booster (Week 4) and after vaccine booster (Week 8)

What was measured

Tumor necrosis factor (TFNα) cytokine concentration levels measures in peripheral blood. Higher TFNα levels is associated with good prognosis.

Analysis population: Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery and response to treatment, and with ≥80% of samples available with measurable cytokine profiles via peripheral blood assay.

Groups in this outcome

α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen

α DC1 vaccine and Chemokine Modulatory Regimen: Celecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\^2 or 20 MU/m\^2 (T-Fri)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen	40

Reported measurements

Prior to vaccine administration (Week 1)

Values in pg/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen	10.8	12.2	Not reported	Not reported	Not reported

Prior to vaccine booster (Week 4)

Values in pg/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen	31.0	5.0	Not reported	Not reported	Not reported

After vaccine booster (Week 8)

Values in pg/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen	17.2	25.4	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
12.2
value
10.8
title
Prior to vaccine administration (Week 1)
categories
measurements
group Id
OG000
spread
5.0
value
31.0
title
Prior to vaccine booster (Week 4)
categories
measurements
group Id
OG000
spread
25.4
value
17.2
title
After vaccine booster (Week 8)

denoms

counts
group Id
OG000
value
40
units
Participants

description

Tumor necrosis factor (TFNα) cytokine concentration levels measures in peripheral blood. Higher TFNα levels is associated with good prognosis.

dispersion Type

Standard Deviation

groups

description
α DC1 vaccine and Chemokine Modulatory Regimen: Celecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\^2 or 20 MU/m\^2 (T-Fri)
id
OG000
title
α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen

param Type

MEAN

population Description

Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery and response to treatment, and with ≥80% of samples available with measurable cytokine profiles via peripheral blood assay.

reporting Status

POSTED

time Frame

Prior to vaccine administration (Week 1), prior to vaccine booster (Week 4) and after vaccine booster (Week 8)

title

Tumor Necrosis Factor (TFNα) Cytokine Levels

type

SECONDARY

unit Of Measure

pg/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice